Claudia Scholl
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Claudia Scholl has a total of 269 co-authors. Here are the top co-authors by number of shared publications:
- Stefan Fröhling
National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany
34 shared publications - Kwang Seok Lee
National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany
17 shared publications - Wolfgang Hartmann
Gerhard-Domagk-Institute of Pathology, Münster University Hospital, Münster, Germany
16 shared publications - Anna Kuntze
Institute of Pathology, University and University Hospital Münster, Münster, Germany
15 shared publications - Bianca Altvater
Department of Pediatric Hematology and Oncology, University Children’s Hospital Muenster, 48149 Muenster, Germany
15 shared publications - Claudia Rossig
Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Muenster, Germany; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands
15 shared publications
Latest Publications
- Open Access
- 5 September 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (36) , eadu2796
Selective targeting of TBXT with DARPins identifies regulatory networks and therapeutic vulnerabilities in chordoma
The embryonic transcription factor TBXT (brachyury) drives chordoma, a spinal neoplasm without effective drug therapies. TBXT’s regulatory network is poorly understood, and strategies to disrupt its activity for therapeutic purposes are lacking. We developed designed ankyrin repeat proteins that block TBXT-DNA binding (T-DARPins). In chordoma cells, T-DARPins reduced cell cycle progression, spheroid formation, and tumor growth in mice and induced signs of senescence and differentiation. Transcriptomic and proteomic analyses identified gene networks involved in cell cycle regulation, embryonic cell identity, and interferon response and revealed features of regulome components, such as susceptibility to pharmacologic inhibition and the fine-tuning of TBXT downstream effectors through IGFBP3. Finally, we found high interferon signaling in chordoma cell lines and patient tumors, which was promoted by TBXT and associated with sensitivity to JAK2 inhibitors. These findings demonstrate the potential of DARPins for probing nuclear proteins to understand the regulatory networks of transcription factor–driven cancers, including entry points for therapies that warrant testing in patients.
- 5 September 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (36) , eadu2796
Open AccessSelective targeting of TBXT with DARPins identifies regulatory networks and therapeutic vulnerabilities in chordoma
The embryonic transcription factor TBXT (brachyury) drives chordoma, a spinal neoplasm without effective drug therapies. TBXT’s regulatory network is poorly understood, and strategies to disrupt its activity for therapeutic purposes are lacking. We developed designed ankyrin repeat proteins that block TBXT-DNA binding (T-DARPins). In chordoma cells, T-DARPins reduced cell cycle progression, spheroid formation, and tumor growth in mice and induced signs of senescence and differentiation. Transcriptomic and proteomic analyses identified gene networks involved in cell cycle regulation, embryonic cell identity, and interferon response and revealed features of regulome components, such as susceptibility to pharmacologic inhibition and the fine-tuning of TBXT downstream effectors through IGFBP3. Finally, we found high interferon signaling in chordoma cell lines and patient tumors, which was promoted by TBXT and associated with sensitivity to JAK2 inhibitors. These findings demonstrate the potential of DARPins for probing nuclear proteins to understand the regulatory networks of transcription factor–driven cancers, including entry points for therapies that warrant testing in patients.
- Open Access
- 16 June 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-20
Somatic gene delivery faithfully recapitulates a molecular spectrum of high-risk sarcomas
A major challenge hampering therapeutic advancements for high-risk sarcoma patients is the broad spectrum of molecularly distinct sarcoma types and the corresponding lack of suitable model systems. Here we describe the development of a genetically-controlled, yet versatile mouse modeling platform allowing delivery of different genetic lesions by muscle electroporation (EPO) in wildtype mice. This EPO-GEMM (EPO-based genetically engineered mouse model) platform allows the generation of ten genetically distinct sarcomas on an isogenic background, including the first model of ETV6::NTRK3-driven sarcoma. Comprehensive histological and molecular profiling reveals that this mouse sarcoma cohort recapitulates a spectrum of molecularly diverse sarcomas with gene fusions acting as major determinants of sarcoma biology. Integrative cross-species analyses show faithful recapitulation of human sarcoma subtypes, including expression of relevant immunotherapy targets. Comparison of syngeneic allografting methods enables reliable preservation and scalability of sarcoma-EPO-GEMMs for preclinical treatment trials, such as NTRK inhibitor therapy in an immunocompetent background.
- 16 June 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-20
Open AccessSomatic gene delivery faithfully recapitulates a molecular spectrum of high-risk sarcomas
A major challenge hampering therapeutic advancements for high-risk sarcoma patients is the broad spectrum of molecularly distinct sarcoma types and the corresponding lack of suitable model systems. Here we describe the development of a genetically-controlled, yet versatile mouse modeling platform allowing delivery of different genetic lesions by muscle electroporation (EPO) in wildtype mice. This EPO-GEMM (EPO-based genetically engineered mouse model) platform allows the generation of ten genetically distinct sarcomas on an isogenic background, including the first model of ETV6::NTRK3-driven sarcoma. Comprehensive histological and molecular profiling reveals that this mouse sarcoma cohort recapitulates a spectrum of molecularly diverse sarcomas with gene fusions acting as major determinants of sarcoma biology. Integrative cross-species analyses show faithful recapitulation of human sarcoma subtypes, including expression of relevant immunotherapy targets. Comparison of syngeneic allografting methods enables reliable preservation and scalability of sarcoma-EPO-GEMMs for preclinical treatment trials, such as NTRK inhibitor therapy in an immunocompetent background.
- Open Access
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Exploiting WEE1 Kinase Activity as FUS::DDIT3-Dependent Therapeutic Vulnerability in Myxoid Liposarcoma
Supplementary Figure S3. Supplementary Figure S3. In vivo efficacy of WEE 1 inhibition in MLS CAM xenografts.
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Exploiting WEE1 Kinase Activity as FUS::DDIT3-Dependent Therapeutic Vulnerability in Myxoid Liposarcoma
Supplementary Figure S3. Supplementary Figure S3. In vivo efficacy of WEE 1 inhibition in MLS CAM xenografts.
- Open Access
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Exploiting WEE1 Kinase Activity as FUS::DDIT3-Dependent Therapeutic Vulnerability in Myxoid Liposarcoma
Supplementary Table S4. Statistical correlation analysis by means of χ².
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Exploiting WEE1 Kinase Activity as FUS::DDIT3-Dependent Therapeutic Vulnerability in Myxoid Liposarcoma
Supplementary Table S4. Statistical correlation analysis by means of χ².
- Open Access
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Exploiting WEE1 Kinase Activity as FUS::DDIT3-Dependent Therapeutic Vulnerability in Myxoid Liposarcoma
Supplementary Table S7. Densitometric analysis of western blot results (Supplementary figure S2). Dose-dependent sensitivity of MLS cells to pharmacologic inhibition of WEE1 activity and cellular localization.
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Exploiting WEE1 Kinase Activity as FUS::DDIT3-Dependent Therapeutic Vulnerability in Myxoid Liposarcoma
Supplementary Table S7. Densitometric analysis of western blot results (Supplementary figure S2). Dose-dependent sensitivity of MLS cells to pharmacologic inhibition of WEE1 activity and cellular localization.
- Open Access
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Exploiting WEE1 Kinase Activity as FUS::DDIT3-Dependent Therapeutic Vulnerability in Myxoid Liposarcoma
Supplementary Figure S1. WEE 1 expression correlates with histological grade of MLS.
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Exploiting WEE1 Kinase Activity as FUS::DDIT3-Dependent Therapeutic Vulnerability in Myxoid Liposarcoma
Supplementary Figure S1. WEE 1 expression correlates with histological grade of MLS.
- Open Access
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Exploiting WEE1 Kinase Activity as FUS::DDIT3-Dependent Therapeutic Vulnerability in Myxoid Liposarcoma
Supplementary Figure S6. CDK 2 expression exacerbates replication stress in MLS.
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Exploiting WEE1 Kinase Activity as FUS::DDIT3-Dependent Therapeutic Vulnerability in Myxoid Liposarcoma
Supplementary Figure S6. CDK 2 expression exacerbates replication stress in MLS.
- Open Access
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Exploiting WEE1 Kinase Activity as FUS::DDIT3-Dependent Therapeutic Vulnerability in Myxoid Liposarcoma
Supplementary Table S5. Densitometric analysis of western blot results (Figure 3A). WEE1 activity is required for genomic integrity and survival of MLS 402-91 (left) and MLS 1765-92 (right) cells.
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Exploiting WEE1 Kinase Activity as FUS::DDIT3-Dependent Therapeutic Vulnerability in Myxoid Liposarcoma
Supplementary Table S5. Densitometric analysis of western blot results (Figure 3A). WEE1 activity is required for genomic integrity and survival of MLS 402-91 (left) and MLS 1765-92 (right) cells.
- Open Access
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Data from Exploiting WEE1 Kinase Activity as FUS::DDIT3-Dependent Therapeutic Vulnerability in Myxoid Liposarcoma
Purpose:The pathognomonic FUS::DDIT3 fusion protein drives myxoid liposarcoma (MLS) tumorigenesis via aberrant transcriptional activation of oncogenic signaling. As FUS::DDIT3 has so far not been pharmacologically tractable to selectively target MLS cells, this study investigated the functional role of the cell cycle regulator WEE1 as novel FUS::DDIT3-dependent therapeutic vulnerability in MLS.Experimental Design:Immunohistochemical evaluation of the cell cycle regulator WEE1 was performed in a large cohort of MLS specimens. FUS::DDIT3 dependency and biological function of the G1/S cell cycle checkpoint were analyzed in a mesenchymal stem cell model and liposarcoma cell lines in vitro. WEE1 activity was modulated by RNAi-mediated knockdown and the small molecule inhibitor MK-1775 (adavosertib). An established MLS cell line–based chicken chorioallantoic membrane model was employed for in vivo confirmation.Results:We demonstrate that enhanced WEE1 pathway activity represents a hallmark of FUS::DDIT3-expressing cell lines as well as MLS tissue specimens and that WEE1 is required for MLS cellular survival in vitro and in vivo. Pharmacologic inhibition of WEE1 activity results in DNA damage accumulation and cell cycle progression forcing cells to undergo apoptotic cell death. In addition, our results uncover FUS::DDIT3-dependent WEE1 expression as an oncogenic survival mechanism to tolerate high proliferation and resulting replication stress in MLS. Fusion protein–driven G1/S cell cycle checkpoint deregulation via overactive Cyclin E/CDK2 complexes thereby contributes to enhanced WEE1 inhibitor sensitivity in MLS.Conclusions:Our preclinical study identifies WEE1-mediated replication stress tolerance as molecular vulnerability in FUS::DDIT3-driven MLS tumorigenesis that could represent a novel target for therapeutic intervention.
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Exploiting WEE1 Kinase Activity as FUS::DDIT3-Dependent Therapeutic Vulnerability in Myxoid Liposarcoma
Purpose:The pathognomonic FUS::DDIT3 fusion protein drives myxoid liposarcoma (MLS) tumorigenesis via aberrant transcriptional activation of oncogenic signaling. As FUS::DDIT3 has so far not been pharmacologically tractable to selectively target MLS cells, this study investigated the functional role of the cell cycle regulator WEE1 as novel FUS::DDIT3-dependent therapeutic vulnerability in MLS.Experimental Design:Immunohistochemical evaluation of the cell cycle regulator WEE1 was performed in a large cohort of MLS specimens. FUS::DDIT3 dependency and biological function of the G1/S cell cycle checkpoint were analyzed in a mesenchymal stem cell model and liposarcoma cell lines in vitro. WEE1 activity was modulated by RNAi-mediated knockdown and the small molecule inhibitor MK-1775 (adavosertib). An established MLS cell line–based chicken chorioallantoic membrane model was employed for in vivo confirmation.Results:We demonstrate that enhanced WEE1 pathway activity represents a hallmark of FUS::DDIT3-expressing cell lines as well as MLS tissue specimens and that WEE1 is required for MLS cellular survival in vitro and in vivo. Pharmacologic inhibition of WEE1 activity results in DNA damage accumulation and cell cycle progression forcing cells to undergo apoptotic cell death. In addition, our results uncover FUS::DDIT3-dependent WEE1 expression as an oncogenic survival mechanism to tolerate high proliferation and resulting replication stress in MLS. Fusion protein–driven G1/S cell cycle checkpoint deregulation via overactive Cyclin E/CDK2 complexes thereby contributes to enhanced WEE1 inhibitor sensitivity in MLS.Conclusions:Our preclinical study identifies WEE1-mediated replication stress tolerance as molecular vulnerability in FUS::DDIT3-driven MLS tumorigenesis that could represent a novel target for therapeutic intervention.
- Open Access
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Exploiting WEE1 Kinase Activity as FUS::DDIT3-Dependent Therapeutic Vulnerability in Myxoid Liposarcoma
Supplementary Table S1. Primary antibodies.
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Exploiting WEE1 Kinase Activity as FUS::DDIT3-Dependent Therapeutic Vulnerability in Myxoid Liposarcoma
Supplementary Table S1. Primary antibodies.